On Aug 15, 2020 10:48 PM, grarpamp <grarpamp@gmail.com> wrote:

https://www.zerohedge.com/political/biden-demands-nationwide-mandate-forces-you-wear-mask-public-all-times

https://www.washingtonexaminer.com/opinion/hydroxychloroquine-works-in-high-risk-patients-and-saying-otherwise-is-dangerous

https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwaa093/5847586
https://academic.oup.com/aje/advance-article-pdf/doi/10.1093/aje/kwaa093/33585862/kwaa093.pdf
Accepted manuscript
Opinion: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19
Patients that Should be Ramped-Up Immediately as Key to the Pandemic
Crisis
Harvey A Risch
American Journal of Epidemiology, kwaa093, https://doi.org/10.1093/aje/kwaa093
Published: 27 May 2020
Abstract

More than 1.6 million Americans have been infected with SARS-CoV-2 and
>10 times that number carry antibodies to it. High-risk patients
presenting with progressing symptomatic disease have only
hospitalization treatment with its high mortality. An outpatient
treatment that prevents hospitalization is desperately needed. Two
candidate medications have been widely discussed: remdesivir, and
hydroxychloroquine+azithromycin. Remdesivir has shown mild
effectiveness in hospitalized inpatients, but no trials have been
registered in outpatients. Hydroxychloroquine+azithromycin has been
widely misrepresented in both clinical reports and public media, and
outpatient trials results are not expected until September. Early
outpatient illness is very different than later hospitalized florid
disease and the treatments differ. Evidence about use of
hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in
inpatients, is irrelevant concerning efficacy of the pair in early
high-risk outpatient disease. Five studies, including two controlled
clinical trials, have demonstrated significant major outpatient
treatment efficacy. Hydroxychloroquine+azithromycin has been used as
standard-of-care in more than 300,000 older adults with
multicomorbidities, with estimated proportion diagnosed with cardiac
arrhythmias attributable to the medications 47/100,000 users, of which
estimated mortality is <20%, 9/100,000 users, compared to the 10,000
Americans now dying each week. These medications need to be widely
available and promoted immediately for physicians to prescribe.